|
1）Merchant ML, Perkins BA, Boratyn GM, et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol. 2009; 20: 2065-74
|
|
|
|
2）Krolewski AS, Gohda T, Niewczas MA. Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes. Clin Exp Nephrol. 2014; 18: 571-83
|
|
|
|
|
3）The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329: 977-86
|
|
|
|
|
|
4）Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329: 1456-62
|
|
|
|
|
|
5）de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011; 305: 2532-39
|
|
|
|
|
|
6）Rosolowsky ET, Skupien J, Smiles AM, et al. Risk of ESRD in type 1 diabetes remains high in spite of renoprotection. J Am Soc Nephrol. 2011; 22: 545-53
|
|
|
|
|
|
7）Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor receptors. Cell Signal. 2012; 24: 1297-305
|
|
|
|
|
|
8）Inukai T, Uchida K, Nakajima H, et al. Tumor necrosis factor-α and its receptors contribute to apoptosis of oligodendrocytes in the spinal cord of spinal hyperostotic mouse (twy/twy) sustaining chronic mechanical compression. Spine. 2009; 34: 2848-57
|
|
|
|
|
|
9）Yan M, Xia C, Cheng C, et al. The role of TNF-α and its receptors in the production of Src-suppressed C kinase substrate by rat primary type-2 astrocytes. Brain Res. 2007; 1184: 28-37
|
|
|
|
|
|
10）Chen X, Oppenheim JJ. Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett. 2011; 585: 3611-8
|
|
|
|
|
|
11）Defer N, Azroyan A, Pecker F, et al. TNFR1 and TNFR2 signaling interplay in cardiac myocytes. J Biol Chem. 2007; 282: 35564-73
|
|
|
|
|
|
12）Grell M, Becke FM, Wajant H, et al. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol. 1998; 28: 257-63
|
|
|
|
|
|
13）Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumornecrosis factor-α from cells. Nature. 1997; 385: 729-33
|
|
|
|
|
|
14）Hawari FI, Rouhani FN, Cui X, et al. Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: a mechanism for generation of soluble cytokine receptors. Proc Natl Acad Sci U S A. 2004; 101: 1297-302
|
|
|
|
|
|
15）Lin J, Hu FB, Rimm EB, et al. The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. Kidney Int. 2006; 69: 336-42
|
|
|
|
|
|
16）Ng DP, Fukushima M, Tai BC, et al. Reduced GFR and albuminuria in Chinese type 2 diabetes mellitus patients are both independently associated with activation of the TNF-α system. Diabetologia. 2008; 51: 2318-24
|
|
|
|
|
|
17）Niewczas MA, Ficociello LH, Johnson AC, et al. Serum concentrations of markers of TNFα and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol. 2009; 4: 62-70
|
|
|
|
|
|
18）Tonelli M, Sacks F, Pfeffer M, et al. Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005; 68: 237-45
|
|
|
|
|
|
19）Shankar A, Sun L, Klein BE, et al. Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study. Kidney Int. 2011; 80: 1231-8
|
|
|
|
|
|
20）Lin J, Hu FB, Mantzoros C, et al. Lipid and inflammatory biomarkers and kidney function decline in type 2 diabetes. Diabetologia. 2010; 53: 263-7
|
|
|
|
|
|
21）Gohda T, Niewczas MA, Ficociello LH, et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol. 2012; 23: 516-24
|
|
|
|
|
|
22）Niewczas MA, Gohda T, Skupien J, et al. Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol. 2012; 23: 507-15
|
|
|
|
|
|
23）Saulnier PJ, Gand E, Ragot S, et al. Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: Follow-up of the SURDIAGENE Cohort. Diabetes Care. 2014; 37: 1425-31
|
|
|
|
|
|
24）Forsblom C, Moran J, Harjutsalo V, et al. Added value of soluble tumor necrosis factor alpha receptor-1 as a biomarker of ESRD risk in patients with type 1 diabetes. Diabetes Care. 2014; 37: 2334-42
|
|
|
|
|
|
25）Pavkov ME, Nelson RG, Knowler WC, et al. Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int. 2015; 87: 812-9
|
|
|
|
|
|
26）Lee SM, Yang S, Cha RH, et al. Circulating TNF receptors are significant prognostic biomarkers for idiopathic membranous nephropathy. PLoS One. 2014; 9: e104354
|
|
|
|
|
|
27）Sonoda Y, Gohda T, Suzuki Y, et al. Circulating TNF receptors 1 and 2 are associated with the severity of renal interstitial fibrosis in IgA nephropathy. PLoS One. 2015; 10: e0122212
|
|
|
|
|
|
28）Oh YJ, An JN, Kim CT, et al. Circulating TNF α receptors predict the outcomes of IgA nephropathy: Aprospective cohort study. PLoS One. 2015; 10: e0132826
|
|
|
|
|